Views & Analysis | Perspectives on pharma industry issues

Patients

The critical role pharmacists play in continuity of care for...

One recommended approach to enhancing continuity in BD-I treatment is to deploy coordinated care teams.

R&D

pharmaphorum podcast Episode 249, Michelle Werner, Alltrna

Treating genetic disease at scale with tRNA, with Michelle W...

Michelle Werner, Director of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.

Digital

Why siloed data is stalling the future of smarter healthcare

Siloed data is one of the most significant, yet overlooked, barriers to healthcare growth today.

Sales & Marketing

Sponsored

12 Questions with Steve Sanghera

Steve Sanghera is the CEO and co-founder of Inventus.

Sales & Marketing

When women thrive, we all rise

We need to see advancing women as an intentional multiplication that benefits teams, organisations, and communities.

Sales & Marketing

How data is critical to commercialising drugs for rare disea...

Orphan drugs are designed to treat rare diseases, but “rare” is a relative term.

Oncology

Henar Hevia and Carolyn Sousa at ASCO 2024

ASCO 2024 - Henar Hevia and Carolyn Sousa

The future of cancer care is personalisation. New breakthroughs are increasingly highly targeted, with powerful results, but only for patients with particular genetic markers.

Digital

The new frontier of microbiome-directed human health

The microbiome is ever more frequently spoken about of late, and so the pharmaphorum podcast invited Leo Grady, founder and CEO of Jona, to speak about at-home personal microbiome profiling

Sales & Marketing

Sponsored

12 Questions with Steve Sanghera

Steve Sanghera is the CEO and co-founder of Inventus.

Sales & Marketing

When women thrive, we all rise

We need to see advancing women as an intentional multiplication that benefits teams, organisations, and communities.

Digital

Why siloed data is stalling the future of smarter healthcare

Siloed data is one of the most significant, yet overlooked, barriers to healthcare growth today.

Digital

Sponsored

STEM AI: A new lens on data-led field team performance

The relationship between pharmaceutical field teams and healthcare professionals (HCPs) is evolving rapidly.

Market Access

JPM 2026: What it revealed about biotech’s new reality

JPM 2026 signalled genuine recovery – but not the kind the industry has historically celebrated.

Market Access

What rare disease commercialisation in Europe teaches us - a...

Rare disease launches are the ultimate stress test for European commercialisation.

Oncology

Day One's big bet on tovorafenib just keeps paying off

Now set to be acquired by Servier for $2.5 billion, Day One Bio proves how far a mission-driven biotech with a strong team and good timing can go.

Oncology

Sponsored

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Oncology